JAMA Network
About The Study: The findings of this study show that, after the end of the semaglutide and tirzepatide shortages, compounding facilities have continued to manufacture glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with added ingredients. Compounded GLP-1 RA sourcing is diverse but includes facilities without licenses to perform sterile compounding or that have been subject to recent disciplinary action, posing clinical and regulatory challenges.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
